Roche’s Gazyva Clears FDA, But First Breakthrough Approval Breaks No Speed Barriers
Executive Summary
FDA cleared Roche’s Rituxan follow-on GA101 in roughly six months, the same amount of time as an old-school priority review.
You may also be interested in...
Roche Builds Hematology Pipeline Beyond B-Cell Disease
Roche is not content with replacing its aging Rituxan franchise in blood cancers. At ASCO, the company described its long-term plans to solidify Gazyva as the new CD20 backbone for non-Hodgkin lymphomas while using Venclexta and even newer candidates like targeted therapy idasanutlin to extend into new blood cancer indications – including the high-need acute myeloid leukemia space.
Roche Hits Goal For Gazyva Expansion With Follicular Lymphoma Approval
Sales for Roche’s Rituxan follow-on Gazyva grew substantially in 2015 to $128m, but still pale compared to AbbVie/J&J’s Imbruvica, which is approved for three blood cancers and brought in more than $1bn.
A “Breakthrough” Reality Check: Sponsors Seek FDA Flexibility On Manufacturing, Diagnostics
FDA’s much-anticipated guidance on expedited programs for drug development fills in some blanks on the new breakthrough designation, but simply advising sponsors they will need to pick up the pace on manufacturing plans and development of companion diagnostics leaves aspiring applicants wanting more, stakeholders said at DIA.